Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SERPINE1 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SERPINE1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the *SERPINE1* gene, which encodes Plasminogen Activator Inhibitor-1 (PAI-1). In oncology research, particularly concerning low-grade ovarian serous cancer (LGOSC), SERPINE1 has been identified as a key mediator of adaptive resistance to MEK inhibitors such as trametinib. The induction of SERPINE1 following MEK inhibition appears to facilitate resistance through the activation of the ERK phosphorylation pathway. Experimental knockdown of SERPINE1 using siRNA has been shown to reduce cell proliferation and restore sensitivity to trametinib in resistant cell lines and mouse models. This agent is primarily utilized as a research tool to validate SERPINE1 as a therapeutic target and a potential diagnostic or prognostic biomarker.
- Other names
- PAI-1 siRNAPAI1 siRNAPAI 1 siRNAplasminogen activator inhibitor-1 siRNA
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)
Beyond the preview
Go deeper on SERPINE1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SERPINE1 siRNA.